Showing results (461-470 of 775) with videos related to
Sort By:
Pageof 78
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.Journal of Drugs in Dermatology : JDD|April 7, 2022
Pustular and Erythrodermic Psoriasis in Patients Treated With Oral Glucocorticoids: A Survey of United States DermatologistsKatherine Awh, Christian Albornoz, Kumar Nadhan, et al.Journal of the American Academy of Dermatology|September 1, 2004
Prevalence and relevance of contact dermatitis allergens: a meta-analysis of 15 years of published T.R.U.E. test dataH Alexander Krob, Alan B Fleischer, Ralph D'Agostino, et al.Dermatology (Basel, Switzerland)|August 7, 2009
Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysisNick Bansback, Sonia Sizto, Huiying Sun, et al.Journal of the American Academy of Dermatology|January 19, 2016
Translating psoriasis guidelines into practice: Important gaps revealedReva Bhushan, Mark G Lebwohl, Alice B Gottlieb, et al.Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.Journal of the American Academy of Dermatology|July 6, 2010
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasisDanielle Levine, Zeev Even-Chen, Irina Lipets, et al.Journal of Drugs in Dermatology : JDD|February 21, 2018
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEILLinda Stein Gold, Jerry Bagel, Mark Lebwohl, et al.Journal of the American Academy of Dermatology|April 7, 2007
Water content and other aspects of brittle versus normal fingernailsDana Kazlow Stern, Stephanie Diamantis, Elizabeth Smith, et al.Journal of the American Academy of Dermatology|September 23, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisKenneth B Gordon, Craig L Leonardi, Mark Lebwohl, et al.Pageof 78